Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis

Academic Article

Abstract

  • Filgrastim, or granulocyte colony-stimulating factor, reverses neutropenia associated with human immunodeficiency virus type 1 (HIV-1) and cytomegalovirus (CMV) infections. During a trial of anti-CMV retinitis therapies coadministered with antiretroviral therapy, 2-4 plasma specimens of HIV-1 RNA were collected from 36 HIV-1-infected patients receiving filgrastim to prevent neutropenia and from 36 patients not receiving filgrastim. For both groups, the crude mean and mean rate of change of HIV-1 log10 RNA levels were similar. Adjustment for covariates (CD4+ T cell lymphocytes, virus load at enrollment, level of neutropenia and antiretroviral therapy [mainly non-highly active antiretroviral therapy], and anti-CMV therapy during follow-up) resulted in a mean log10 HIV-1 RNA level for individuals receiving filgrastim versus those not receiving the drug of 5.11 versus 4.87 (P = .12) and respective log mean rates of change per month of -0.08 versus -0.21 (P = .08). This latter difference has borderline statistical significance, which suggests that filgrastim may reduce the decline of HIV-1 RNA loads.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Davidson M; Min YI; Holbrook JT; Van Natta M; Quinn TC; Murphy RL; Welch W; Jabs DA; Carr-Holden LM; Doyle K
  • Start Page

  • 1013
  • End Page

  • 1018
  • Volume

  • 186
  • Issue

  • 7